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Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5
1Hopital COCHIN, Paris, France; 2Cemka, Bourg-La-Reine,
France; 3CEMKA, Bourg la Reine, France; 4Université de
Bretagne-Sud,Vannes, France; 5Alcon, Rueil-Malmaison, France
OBJECTIVES: To estimate the risk of being in institu-
tion with vision impairment. METHODS: Two national
surveys were pooled together: 1) 2075 institutions (chil-
dren or adults with handicap, old people and psychiatric
centers) were selected at random from the French Health
Ministry ﬁles in 18 predeﬁned strata. Of the 15,403 
subjects taken at random, 14,603 interviews (94.9%)
documented handicap; and 2) Level of handicap was doc-
umented in a randomized, stratiﬁed sample of 356,208
citizens living in the community. From this sample,
21,760 subjects were further selected at random and
16,945 persons were interviewed. Handicaps (vision,
audition, speaking, brain, visceral, motor and other) and
activity of daily living (ADL) were then collected. The
odds-ratio (OR) of being in institution was estimated
using stepwise logistic regressions with age, geographical
area, handicaps and ADL as co-variables. RESULTS:
Patients in institution were more often female (64.3%
versus 52.4%) and older (68.7 versus 38.0 years old) then
patient living at home. They more often had handicaps
(OR—speaking: 6.56; brain: 6.39; motor: 4.40; visceral:
2.87; audition: 2.37; other: 1.39). They were less often
able to perform their ADL (46.2% versus 97.1%) without
assistance. The OR to be in institution when having vision
handicap was 8.40 without adjustment. This ﬁgure
became 1.53 after adjustment on age, geographical area
and other handicaps and 1.24 after adjustment on age,
geographical area and ADL. CONCLUSION: Vision
handicap is an independent risk factor of institutional-
ization. Preserving vision on long term might reduce or
postpone old subject’s institutionalization by controlling
incapacity and dependency.
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SCORING OF VISUAL FIELD MEASURED
THROUGH HUMPHREY PERIMETRY: PRINCIPAL
COMPONENT VARIMAX ROTATION FOLLOWED
BY CLUSTERING ANALYSIS
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OBJECTIVES: To issue orthogonal scores from the 52
standardized data collected by a Humphrey visual ﬁeld
(VF) perimetry that maximize between-variance and 
minimize within-variance. METHODS: 437 VF were col-
lected and classiﬁed into 7 clinical groups: irregularities
of VF (IVF), Nasal step (NaS), Arcuate scotoma (AC),
Para-central scotoma (PCS), Blind spot enlargement
(BSE), Diffuse deﬁcit (DD), Advanced deﬁcit (AD).
Number and contents of scores were identiﬁed using a
principal component analysis (Varimax) followed by an
ascending hierarchical clustering analysis. Internal con-
sistency was checked with Cronbach alpha. Scores were
compared across the clinical groups with an Anova.
RESULTS: Patients totaling 54.7% of the patients were
older than 60. Mean defect was -9.21 on average and
PSD was 6.50. Six scores were identiﬁed: 4 peripheral
scores (Nasal Superior NS, Nasal Inferior NI, Temporal
Superior TS, Temporal Inferior TI) and 2 para-central
scores (superior PCSS, inferior PCSI). Cronbach alphas
were always between 0.90 and 0.97. The six scores
decreased simultaneously from IVF, DD to AD. AC had
lower scores in NS, NI and TS. PCS had a lower PCSS.
BSE had lower scores in TS and TI. NaS had lower scores
in NS and NI. CONCLUSION: Six orthogonal scores
were found to be optimal from the Humphrey perimetry
matrix. Internal reliability was good. Ability to discrimi-
nate between clinical subgroups was found. Further
analyses on longitudinal data need to be performed to
conﬁrm our ﬁndings.
EYE DISORDERS—Cost Studies
PAE9
COST AND EFFECTIVENESS OF BRINZOLAMIDE
VERSUS DORZOLAMIDE IN THE TREATMENT
OF GLAUCOMA: AN ANALYSIS CONDUCTED
USING THE UNITED-KINGDOM GENERAL
PRACTITIONER RESEARCH DATABASE
Lafuma A1,Voinet C1, Berdeaux G2
1Cemka, Bourg-La-Reine, France; 2Alcon, Rueil-Malmaison,
France
OBJECTIVE: To compare the cost and effectiveness of
brinzolamide and dorzolamide using data collected in the
United-Kingdom General Practitioner Research Database
METHODS: Files of patients with a diagnosis of ocular
hypertension or glaucoma, or treated with a topical IOP
lowering treatment were extracted. Patients starting treat-
ment with dorzolamide or brinzolamide from August
2000 were selected. A treatment failure was deﬁned as a
regimen change (adding or removing a topical treatment).
Time to treatment failure was compared using a Cox
model. The economic perspective was that of the NHS.
The annual cost of therapy changes by treatment line
(ﬁrst, second, etc.) was calculated for year 2000; visit,
medication and hospitalization costs were included.
RESULTS: Of 49,799 patients selected, 146 were treated
with brinzolamide and 1230 with dorzolamide. No sta-
tistically signiﬁcant differences were found between the 2
groups in terms of patient and disease characteristics.
Patients averaged 72.9 years old and were 56% female.
Prescriptions totaling 21.1% of the prescriptions involved
monotherapy and 14.8% were for ﬁrst line treatment.
After 1 year, 29.8% of the brinzolamide patients experi-
enced a treatment failure compared to 46.0% with 
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dorzolamide (P < 0.01). Seventy-ﬁve percent of the
patients had a treatment duration longer than 203 days
when treated with brinzolamide versus 140 days with
dorzolamide. The probability of a failure was 1.61 (P <
0.02) times higher with dorzolamide, after adjusting for
treatment line and the number of drugs prescribed. The
yearly glaucoma treatment cost for a patient with a treat-
ment failure was found to be higher (GBP 15.21) than for
patients who continued their treatment. CONCLUSION:
In comparison to dorzolamide, patients treated with brin-
zolamide experienced fewer treatment failures, leading to
cost savings.
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COMPARISON OF THE CLINICAL EFFICACY
AND COST-EFFECTIVENESS OF LUMIGAN AND
XALATAN IN THE TREATMENT OF GLAUCOMA
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OBJECTIVES: The purpose of this study was to com-
pare the intraocular pressure (IOP)—lowering efﬁcacy
and cost-effectiveness of Lumigan (Bimatoprost) 
versus Xalatan (Latanoprost) in glaucoma patients.
METHODS: A Markov model was developed to compare
the cost-effectiveness of Lumigan initiated treatment with
Xalatan initiated treatment in the context of the French
Health care system. The model uses a timeframe of one
year and data from published randomised clinical trials,
which included a total of 249 patients. Patients were
allowed to switch medication up to a maximum of two
times if target IOP was not met or adverse events occurred
and each switch was associated with a physician visit
(cost: €23.00 each). Drug costs used were €20.10 for
Lumigan and €17.67 for Xalatan. A probabilistic analy-
sis was performed using 1000 Monte Carlo simulations.
The primary outcome measures were the number of
months patients spent at IOP < 17mmHg and the cost
per month at IOP < 17mmHg. Sensitivity analyses were
conducted varying the target IOPs. RESULTS: More
patient months at IOP < 17mmHg were achieved by
patients on Lumigan versus Xalatan initiated therapy (9.7
versus 9.3; P < 0.05). Lumigan initiated therapy was also
associated with fewer annual physician visits per patient
(5.14 compared to 5.48; P < 0.001). The cost per patient
per month at IOP < 17mmHg was €41.96 for patients on
Lumigan compared to €44.60 for those on a Xalatan ini-
tiated therapy. The results of the sensitivity analysis deter-
mined that at target IOPs of 14 to 17mmHg there was a
lower average annual treatment cost per patient for
Lumigan initiated patients. CONCLUSIONS: Lumigan
initiated treatment is more cost-effective than Xalatan ini-
tiated treatment at target IOPs between 14–17mmHg.
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OBJECTIVE: The aim of glaucoma treatment is to delay
progression of the disease to blindness, by lowering 
intra-ocular pressure (IOP). Clinical trials have shown
that latanoprost (Xalatan®, Pﬁzer) achieves better IOP
control than beta-blockers. We assessed the cost-
effectiveness of latanoprost as 1st-line therapy, compared
to beta-blockers, in Austria, Belgium, France, Germany,
Italy and the UK. METHODS: Clinical outcomes and
resource utilisation data were obtained from a retrospec-
tive chart review study of glaucoma patients initially
treated with latanoprost or beta-blocker in Germany,
Italy, Spain, and the UK. A Markov model was used to
calculate the number of months of IOP control and total
costs (including drugs, physician visits, diagnostic tests
and surgeries) per patient over 2 years from a third-party
payer perspective. The model was estimated by Monte
Carlo simulation. The incremental cost per IOP-
controlled month was reported for each country and 
variability around this ratio was examined. RESULTS:
Seventy-three percent of patients remained on treatment
with latanoprost, compared to 29% with beta-blocker,
over 2 years. The higher acquisition cost of latanoprost
was partly offset by lower surgery costs. The ICER ranged
from €24.94 (95% CI: 20.68–30.11) per IOP-controlled
month, for France, to €272.84 (251.24–297.17), for
Germany. Sensitivity analyses showed that survival on
therapy, the duration of medication bottles and parame-
ters related to surgery costs were the main drivers of 
cost-effectiveness. CONCLUSIONS: Differences between
countries were mainly attributable to variation in drug
and surgery unit costs. First-line treatment with
latanoprost is predicted to be cost-effective if decision-
makers value the control of IOP at a minimum of approx-
imately €25 per month in France, €45 per month in
Belgium, UK and €275 per month in Germany, under the
current system and costs of care. Relatively low unit costs
for surgery and the drug co-payment system contributed
to the higher ICER in Germany.
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TREATMENT DURATION AS A COST DRIVER OF
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PERSPECTIVE IN FRANCE, GERMANY AND THE
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